The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-small Cell Lung Cancer Drugs Market Research Report 2025
Synopsis
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
The global Non-small Cell Lung Cancer Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-small Cell Lung Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-small Cell Lung Cancer Drugs.
Report Scope
The Non-small Cell Lung Cancer Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-small Cell Lung Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-small Cell Lung Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Segment by Type
Biologics
Small Molecule Targeted Therapy
Chemotherapy
Other
Segment by Application
Lung Adenocarcinoma
Squamous Cell Lung Carcinoma
Large-cell Lung Carcinoma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-small Cell Lung Cancer Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.
The global Non-small Cell Lung Cancer Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-small Cell Lung Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-small Cell Lung Cancer Drugs.
Report Scope
The Non-small Cell Lung Cancer Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-small Cell Lung Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-small Cell Lung Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Segment by Type
Biologics
Small Molecule Targeted Therapy
Chemotherapy
Other
Segment by Application
Lung Adenocarcinoma
Squamous Cell Lung Carcinoma
Large-cell Lung Carcinoma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-small Cell Lung Cancer Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-small Cell Lung Cancer Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Biologics
1.2.3 Small Molecule Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Other
1.3 Market by Application
1.3.1 Global Non-small Cell Lung Cancer Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Lung Adenocarcinoma
1.3.3 Squamous Cell Lung Carcinoma
1.3.4 Large-cell Lung Carcinoma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-small Cell Lung Cancer Drugs Market Perspective (2019-2030)
2.2 Non-small Cell Lung Cancer Drugs Growth Trends by Region
2.2.1 Global Non-small Cell Lung Cancer Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-small Cell Lung Cancer Drugs Historic Market Size by Region (2019-2024)
2.2.3 Non-small Cell Lung Cancer Drugs Forecasted Market Size by Region (2025-2030)
2.3 Non-small Cell Lung Cancer Drugs Market Dynamics
2.3.1 Non-small Cell Lung Cancer Drugs Industry Trends
2.3.2 Non-small Cell Lung Cancer Drugs Market Drivers
2.3.3 Non-small Cell Lung Cancer Drugs Market Challenges
2.3.4 Non-small Cell Lung Cancer Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-small Cell Lung Cancer Drugs Players by Revenue
3.1.1 Global Top Non-small Cell Lung Cancer Drugs Players by Revenue (2019-2024)
3.1.2 Global Non-small Cell Lung Cancer Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Non-small Cell Lung Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-small Cell Lung Cancer Drugs Revenue
3.4 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio
3.4.1 Global Non-small Cell Lung Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Drugs Revenue in 2023
3.5 Non-small Cell Lung Cancer Drugs Key Players Head office and Area Served
3.6 Key Players Non-small Cell Lung Cancer Drugs Product Solution and Service
3.7 Date of Enter into Non-small Cell Lung Cancer Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-small Cell Lung Cancer Drugs Breakdown Data by Type
4.1 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Type (2019-2024)
4.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Type (2025-2030)
5 Non-small Cell Lung Cancer Drugs Breakdown Data by Application
5.1 Global Non-small Cell Lung Cancer Drugs Historic Market Size by Application (2019-2024)
5.2 Global Non-small Cell Lung Cancer Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-small Cell Lung Cancer Drugs Market Size (2019-2030)
6.2 North America Non-small Cell Lung Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-small Cell Lung Cancer Drugs Market Size by Country (2019-2024)
6.4 North America Non-small Cell Lung Cancer Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-small Cell Lung Cancer Drugs Market Size (2019-2030)
7.2 Europe Non-small Cell Lung Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2019-2024)
7.4 Europe Non-small Cell Lung Cancer Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size (2019-2030)
8.2 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-small Cell Lung Cancer Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-small Cell Lung Cancer Drugs Market Size (2019-2030)
9.2 Latin America Non-small Cell Lung Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-small Cell Lung Cancer Drugs Market Size by Country (2019-2024)
9.4 Latin America Non-small Cell Lung Cancer Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size (2019-2030)
10.2 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-small Cell Lung Cancer Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Non-small Cell Lung Cancer Drugs Introduction
11.1.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Drugs Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Detail
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Non-small Cell Lung Cancer Drugs Introduction
11.2.4 Bristol-Myers Squibb Company Revenue in Non-small Cell Lung Cancer Drugs Business (2019-2024)
11.2.5 Bristol-Myers Squibb Company Recent Development
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Detail
11.3.2 Eli Lilly and Company Business Overview
11.3.3 Eli Lilly and Company Non-small Cell Lung Cancer Drugs Introduction
11.3.4 Eli Lilly and Company Revenue in Non-small Cell Lung Cancer Drugs Business (2019-2024)
11.3.5 Eli Lilly and Company Recent Development
11.4 F. Hoffmann-La Roche Ltd
11.4.1 F. Hoffmann-La Roche Ltd Company Detail
11.4.2 F. Hoffmann-La Roche Ltd Business Overview
11.4.3 F. Hoffmann-La Roche Ltd Non-small Cell Lung Cancer Drugs Introduction
11.4.4 F. Hoffmann-La Roche Ltd Revenue in Non-small Cell Lung Cancer Drugs Business (2019-2024)
11.4.5 F. Hoffmann-La Roche Ltd Recent Development
11.5 Merck & Co., Inc.
11.5.1 Merck & Co., Inc. Company Detail
11.5.2 Merck & Co., Inc. Business Overview
11.5.3 Merck & Co., Inc. Non-small Cell Lung Cancer Drugs Introduction
11.5.4 Merck & Co., Inc. Revenue in Non-small Cell Lung Cancer Drugs Business (2019-2024)
11.5.5 Merck & Co., Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
